Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

4.12USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$4.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
112,942
52-wk High
$7.67
52-wk Low
$3.92

Chart for

About

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical... (more)

Overall

Beta: 3.45
Market Cap(Mil.): $273.92
Shares Outstanding(Mil.): 43.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage:

11 Jan 2018

BRIEF-Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic

* ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC

20 Dec 2017

BRIEF-Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria

* ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY

15 Dec 2017

BRIEF-Aratana Therapeutics Announces Proposed Public Offering

* ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

27 Nov 2017

BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE

* ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE

10 Nov 2017

BRIEF-Aratana Therapeutics reports Q3 loss per share of $0.21

* Aratana Therapeutics reports third quarter 2017 financial results

02 Nov 2017

BRIEF-Aratana Therapeutics announces launch of Entyce

* Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution)

13 Oct 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.80 -0.66
Merck & Co., Inc. (MRK.N) $54.98 -1.31
Bayer AG (BAYGn.DE) €98.02 -0.91
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.06 -0.49
Eli Lilly and Co (LLY.N) $77.55 -1.42
Zoetis Inc (ZTS.N) $80.35 +0.62
Virbac SA (VIRB.PA) €122.60 -0.40
Vetoquinol SA (VETO.PA) €51.00 -1.40
Dechra Pharmaceuticals plc (DPH.L) 2,260.00 +8.00

Earnings vs. Estimates